| Initial 17beta-estradiol dose for treating vasomotor symptoms. | |
| | |
MedLine Citation:
|
PMID: 10775738 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the efficacy of different doses of 17beta-estradiol (E2) for relief of vasomotor symptoms in menopausal women. METHODS: This was a randomized, double-masked, placebo-controlled, 12-week study in which 333 menopausal women with moderate or severe hot flushes were assigned to treatment with 0.25 mg, 0.5 mg, 1 mg, or 2 mg oral micronized 17beta-E2, or placebo. The number and severity of hot flushes were recorded daily. RESULTS: There was a significant linear correlation between increased dosage of 17beta-E2 and decreased moderate to severe hot flushes per week (P <.001). Rapid reduction in moderate to severe hot flushes was only achieved with 1 and 2 mg, showing a significant difference from placebo at week 4 (P <.05). At week 4, half the women on placebo had reduced moderate to severe hot flushes of at least 52%; the corresponding figures were 56%, 69%, 86%, and 91% for 0.25, 0.5, 1, and 2 mg, respectively. At week 12, all doses except 0.25 mg were significantly better than placebo for reducing moderate to severe hot flushes (P <.001). Although there were no significant differences, twice as many women in the 2-mg group discontinued treatment due to adverse events, compared with the placebo group. CONCLUSION: Oral micronized 17beta-E2 showed a dose-response effect for reducing moderate and severe hot flushes in menopausal women. 17beta-E2 1 mg appeared to be the most useful initial dose. |
| | |
Authors:
|
M Notelovitz; J P Lenihan; M McDermott; I J Kerber; N Nanavati; J Arce |
Related Documents
:
|
9141518 - Mk-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrat... 17479608 - Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal... 20647478 - A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effe... 17162058 - Sildenafil affects olfactory function. 12507658 - Intrauterine growth retardation and lack of teratogenic effects of prenatal exposure to... 1358918 - Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazos... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 95 ISSN: 0029-7844 ISO Abbreviation: Obstet Gynecol Publication Date: 2000 May |
Date Detail:
|
Created Date: 2000-05-22 Completed Date: 2000-05-22 Revised Date: 2009-10-26 |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 726-31 Citation Subset: AIM; IM |
Affiliation:
|
Women's Medical and Diagnostic Center, The Climacteric Clinic, Gainesville, Florida, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Dose-Response Relationship, Drug Double-Blind Method Estradiol / administration & dosage* Estrogen Replacement Therapy* Female Hot Flashes / drug therapy* Humans Menopause* Middle Aged |
| Chemical | |
Reg. No./Substance:
|
50-28-2/Estradiol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship between body fat distribution and bone mineral density in premenopausal Japanese women.
Next Document: Estrogen therapy in women undergoing coronary artery bypass grafting: effect on surgical complicatio...